124863-80-5

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 78168-82-8 ethyl 3-amino-4-methyl-pent-2-enoate 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 122930-45-4 (E)-2-<(4-fluorophenyl)methylene>-4-methyl-3-oxopentanoic acid ethyl ester 
• 124863-78-1 diethyl 4-(4-fluorophenyl)-2,6-diisopropyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 124863-79-2 diethyl 4-(4-fluorophenyl)-2,6-diisopropylpyridine-3,5-dicarboxylate 

Downstream Products

• 202856-04-0 ethyl 2,6-Diisopropyl-4-(4-fluorophenyl)-3-formyl-pyridine-5-carboxylate 
• 916314-39-1 ethyl 4-(4-fluorophenyl)-2,6-diisopropyl-5-[(d3-methoxy)methyl]nicotinate 
• 916314-40-4 (4-(4-fluorophenyl)-2,6-diisopropyl-5-[(d3-methoxy)methyl]pyridin-3-yl)methanol 
• 916314-41-5 3-(bromomethyl)-4-(4-fluorophenyl)-2,6-diisopropyl-5-[(d3-methoxy)methyl]pyridine 
• 916314-42-6 3-((diphenylphosphoryl)methyl)-4-(4-fluorophenyl)-2,6-diisopropyl-5-[(d3-methoxy)methyl]pyridine 
• 916314-44-8 (4R,6S,E)-6-(2-(4-(4-fluorophenyl)-2,6-diisopropyl-5-[(d3-methoxy)methyl]-pyridin-3-yl)vinyl)-4-hydroxy-tetrahydropyran-2-one 
• 916314-43-7 tert-butyl 2-((4R,6S)-6-((E)-2-(4-(4-fluorophenyl)-2,6-diisopropyl-5-[(d3-methoxy)methyl]pyridin-3-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 202853-45-0 [4-(4-Fluoro-phenyl)-2,6-diisopropyl-5-((E)-propenyl)-pyridin-3-yl]-methanol 
• 202853-46-1 2,6Diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-ethenylpyridine 
• 202853-44-9 [5-((E)-But-1-enyl)-4-(4-fluoro-phenyl)-2,6-diisopropyl-pyridin-3-yl]-methanol 
• 334932-60-4 [4-(4-Fluoro-phenyl)-2,6-diisopropyl-5-((E)-3-methyl-but-1-enyl)-pyridin-3-yl]-methanol 
• 202853-48-3 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5butylpyridine 
• 202857-51-0 2,6-diisopropyl-4-(4-fluorophenyl)-5-pentyl-3-pyridinecarboxaldehyde 
• 202857-40-7 [4-(4-Fluoro-phenyl)-2,6-diisopropyl-5-((E)-pent-1-enyl)-pyridin-3-yl]-methanol 

Relevant academic research and scientific papers

Synthesis of d3-cerivastatin for use as internal standard in a LC/MS/MS method developed for quantitation of the drug in human serum

d3-Cerivastatin was synthesized as an internal standard for use in a LC/MS/MS method developed for the simultaneous quantitative determination of the drug in human serum. d3-Cerivastatin was efficiently prepared on large scale from d

Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists

5-Hydroxyalkyl-4-phenylpyridines have been identified as a novel class of glucagon antagonists with potential utility for the treatment of diabetes. A lead structure with moderate activity was discovered through a high throughput screening assay. Structure-activity relationships led to the discovery of a potent antagonist, IC50=0.11 μM, more than 60-fold improvement over the lead structure.

Substituted biphenyls

Substituted biphenyls having glucagon receptor antagonistic activity. Claimed compounds have the formula wherein R1aand R1bindependently represent (C1-C6) alkyl; R2represents (C1-C10) alkyl or substituted (C1-C10) alkyl wherein the substituents are independently from 1 to 3 of —SR7; R7represents phenyl, or substituted phenyl wherein the substituents are independently 1-5 of halogen, trifluoromethyl, (C1-C6) alkyl, (C1-C6) alkoxy, nitro, cyano, or hydroxyl; R3represents substituted (C1-C6) alkyl wherein the substituents are 1-2 hydroxyl groups; G represents a substituent selected from the group consisting of halogen, (C1-C6) alkyl, and OR4wherein R4is H or (C1-C6) alkyl; and y is 0 or an integer of 1-3. Pharmaceutical compositions containing such compounds and methods of treatment of glucagon-mediated conditions by administering such compounds are also claimed.

7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis

Novel compounds for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis of the formula STR1 in which A, B, D and E can have varied meanings, X is --CH2 --CH2 or --CH=CH--, and R is STR2 wherein R21 denotes hyd

CERTAIN 7-[2,6-DIISOPROPYL-4-PHENYL-5-LOWER ALKOXYMETHYL-PYRID-3-YL]-3,5-DIHYDROXY-6-ENOATES AND DERIVATIVES USEFUL FOR TREATING CIRCULATORY DISEASES

Novel compounds for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis of the formula (I) in which A, B, D and E can have varied meanings, X is -CH2-CH2 or -CH=CH-, and R is wherein R21 denotes hydrogen or alkyl and R22 denotes hydrogen, denotes alkyl, aryl or aralkyl, or denotes a cation, and their oxidation products

HMG-COA REDUCTASE-INHIBITING IMINO-SUBSTITUTED PYRIDINES

HMG-CoA reductase-inhibiting imino-substituted pyridines of the formula STR1 in which R 1 is optionally substituted aryl, R 2 is optionally substituted aryl or alkyl, OH, alkoxy, aralkoxy, or optionally substituted aryloxy,R. sup.